Trial · NCT00066469
Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
NCT00066469, Phase 2, Completed, Children's Oncology Group; results first posted 2014-01-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation. Trials, record NCT00066469. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00066469
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
- NCT number
- NCT00066469
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 55 participants, actual
- Lead sponsor
- Children's Oncology Group
- Conditions
- Lymphoproliferative Disorder
- Interventions
- rituximab, cyclophosphamide, methylprednisolone, prednisone
- First posted
- 2003-08-07
- Last updated
- 2019-08-06
- Results first posted
- 2014-01-17
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Event-free Survival | 2 years | Alive in continuous complete remission with functioning original allograft. The Event Free Survival (EFS) will be estimated by the Kaplan-Meier method. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Event-free Survival | 2 years | One patient out of the 55 patients enrolled was ineligible for study and therefore was excluded from analysis. | percentage of participants analyzed | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Event-free Survival | Cyclophosphamide, Prednisone, Rituximab | 71 | 95% Confidence Interval 57 to 82 | percentage of participants analyzed |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cyclophosphamide, Prednisone, Rituximab | 55 | |
| Overall Study | COMPLETED | Cyclophosphamide, Prednisone, Rituximab | 39 | |
| Overall Study | NOT COMPLETED | Cyclophosphamide, Prednisone, Rituximab | 16 |
Source ClinicalTrials.gov
Adverse events69
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Cyclophosphamide, Prednisone, Rituximab | 3 | 54 | 3 |
| other | Blood and lymphatic system disorders - Other, specify | Blood and lymphatic system disorders | Cyclophosphamide, Prednisone, Rituximab | 1 | 54 | 1 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Cyclophosphamide, Prednisone, Rituximab | 12 | 54 | 12 |
| other | Sinus tachycardia | Cardiac disorders | Cyclophosphamide, Prednisone, Rituximab | 1 | 54 | 1 |
| other | Abdominal distension | Gastrointestinal disorders | Cyclophosphamide, Prednisone, Rituximab | 1 | 54 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Cyclophosphamide, Prednisone, Rituximab | 2 | 54 | 2 |
| other | Gastrointestinal disorders - Other, specify | Gastrointestinal disorders | Cyclophosphamide, Prednisone, Rituximab | 1 | 54 | 1 |
| other | Lower gastrointestinal hemorrhage | Gastrointestinal disorders | Cyclophosphamide, Prednisone, Rituximab | 1 | 54 | 1 |
| other | Mucositis oral | Gastrointestinal disorders | Cyclophosphamide, Prednisone, Rituximab | 1 | 54 | 1 |
| other | Nausea | Gastrointestinal disorders | Cyclophosphamide, Prednisone, Rituximab | 1 | 54 | 1 |
1 to 10 of 69Source ClinicalTrials.gov
See all 69 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cyclophosphamide, Prednisone, Rituximab | ||
| Total, other adverse events | Cyclophosphamide, Prednisone, Rituximab | 38 | 54 |
| Total, serious adverse events | Cyclophosphamide, Prednisone, Rituximab | 2 | 54 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22883417 | RESULT |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U10CA098543 | Children's Oncology Group Chair's Grant | ADAMSON, PETER C. | CHILDREN'S HOSP OF PHILADELPHIA | NATIONAL CANCER INSTITUTE | 2003 to 2013 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00066469
GET https://conductscience.org/api/trials/v1/NCT00066469/events?page=2